Hutchmed Announces Agreement with China National Healthcare Security Administration for Continued Inclusion of Elunate and Addition of Sulanda in the National Reimbursement Drug List in China
December 03, 2021 at 07:00 am
HUTCHMED (China) Limited announced that, following the 2021 negotiations with the China National Healthcare Security Administration on January 1, 2022 the updated National Reimbursement Drug List will continue to include ELUNATE and will now include SULANDA. ELUNATE was first included in the NRDL on January 1, 2020, for the treatment of metastatic colorectal cancer. CRC was the third most diagnosed form of cancer by incidence in China in 2020, with an estimated 450,000 to 550,000 new cases each year. HUTCHMED's third oncology drug, ORPATHYS? (savolitinib), is the first and only approved MET inhibitor in China for the treatment of patients with non-small cell lung cancer with MET exon 14 skipping alterations.